30
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery

      , , , , ,
      International Journal of Pharmaceutics
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In this study liposome coated with low molecular weight chitosan (LCH) was proposed and investigated its in vitro and in vivo properties, and its potential use in ocular drug delivery was evaluated. LCH with a molecular weight of 8kDa was prepared and coated on liposome loaded with diclofenac sodium. The LCH coating changed the liposome surface charge and slightly increased its particle size, while the drug encapsulation was not affected. After coating, the liposome displayed a prolonged in vitro drug release profile. LCH coated liposome also demonstrated an improved physicochemical stability at 25 degrees C in a 30-day storage period. The ocular bioadhesion property was evaluated by rabbit in vivo precorneal retention, and LCH coated liposome achieved a significantly prolonged retention compared with non-coated liposome or drug solution. The LCH coating also displayed a potential penetration enhancing effect for transcorneal delivery of the drug. In the ocular tolerance study, no irritation or toxicity was caused by continual administration of LCH coated liposome in a total period of 7 days. In conclusion, the LCH coating significantly modified the properties of liposome and brought a series of notable advantages for ocular drug delivery.

          Related collections

          Author and article information

          Journal
          International Journal of Pharmaceutics
          International Journal of Pharmaceutics
          Elsevier BV
          03785173
          September 2009
          September 2009
          : 379
          : 1
          : 131-138
          Article
          10.1016/j.ijpharm.2009.06.020
          19559775
          08f8d366-86cd-4b87-a100-d4aa88605d55
          © 2009

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article